Pharmac to Fund Injectable Letermovir for High-Risk Patients
From December 1, Pharmac will offer funding for the injectable version of letermovir, known commercially as Prevymis. This treatment is aimed at preventing cytomegalovirus (CMV) infections in individuals who have undergone allogenic haematopoietic stem cell transplants (allo-HSCT) or who are experiencing severe immunosuppression.
Background on Funding Decisions
The recent decision to extend funding to the injectable formulation follows Pharmac’s prior announcement on May 1, 2026, regarding the availability of letermovir in tablet form. The inclusion of the injectable option is anticipated to address specific challenges, as some patients may struggle with accurate dosing from the tablet version.
Anticipated Impact of Injectable Formulation
Pharmacology Manager Michaela Lion noted that the injectable letermovir is expected to benefit up to 56 patients during its first year of availability. It will be accessible in both hospitals and community pharmacies, making it easier for at-risk individuals to receive the necessary treatment.
Understanding Cytomegalovirus
Cytomegalovirus is commonly encountered during childhood and remains dormant in most individuals. However, it poses significant health risks for those with weakened immune systems, particularly recipients of allo-HSCT. Lion emphasized the importance of preventing CMV reactivation, as successful treatment has been reported since letermovir’s initial funding, with no cases of CMV infection noted among treated patients.
Benefits of Preventing CMV Infections
Preventing CMV infections can significantly reduce the likelihood of severe complications, long hospital stays, and intensive medical treatments. This not only aids in patient recovery at home but also allows them to spend more time with their families, which is invaluable during the healing process.
Further Information
For additional details regarding this funding decision, please visit Pharmac’s official website: Pharmac to Fund Injectable Letermovir.
© Scoop Media
New Zealand’s public broadcaster, delivering comprehensive news and current affairs, alongside specialist audio features and documentaries.
Established under the Radio New Zealand Act 1995, Radio New Zealand (RNZ) provides daily impartial news and information to the public, contributing significantly to the country’s media landscape.
Discussion about this post